Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will publish its Q2 2023 interim report on Wednesday August 23, 2023, before 09:00 CET.
Scandion’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session.
Access to the event can be obtained as follows:
LIVE access on Wednesday August 23, 2023, at 10:00 CET: https://financialhearings.com/event/46155
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
The information was provided by the contact person above for publication on August 16, 2023, at 08.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.